title: Interaction of glutamine 165 in the fourth transmembrane segment of the human neurokinin-1 receptor with quinuclidine antagonists.
abstract: Substance P binds to and activates the neurokinin-1 receptor with high affinity, thereby modulating several neuronal pathways including pain transmission and neurogenic inflammation. Several high affinity non-peptide antagonists have recently been described. To elucidate the molecular interactions specific for binding to the neurokinin-1 receptor, site-directed mutagenesis has been utilized to identify amino acid residues that interact directly with antagonists. Glutamine 165 in the fourth transmembrane segment was shown to be critical for the binding of CP-96,345 but not SR140333. Analysis of quinuclidine analogs suggests that glutamine 165 interacts with the C-3 heteroatom in this class of antagonists, probably through a hydrogen bond. Glutamine 165 also plays a minor role in the binding of peptides and RP67580. In contrast, serine 169 was determined to be critical for the binding of RP67580. These data indicate that residues 165 and 169 in the fourth transmembrane segment, along with residues in the fifth, sixth, and seventh transmembrane segments as demonstrated previously, form the non-peptide antagonist binding site in the neurokinin-1 receptor. Furthermore, the antagonist binding site overlaps with the binding site for peptide agonists in the fourth and seventh transmembrane segments.
authors.affiliation: Department of Molecular Pharmacology and Biochemistry, Merck Research Laboratories, Rahway, New Jersey 07065.
authors.forename: T M
authors.initials: TM
authors.lastname: Fong
authors.forename: H
authors.initials: H
authors.lastname: Yu
authors.forename: M A
authors.initials: MA
authors.lastname: Cascieri
authors.forename: D
authors.initials: D
authors.lastname: Underwood
authors.forename: C J
authors.initials: CJ
authors.lastname: Swain
authors.forename: C D
authors.initials: CD
authors.lastname: Strader
mesh_terms: D000595:Amino Acid Sequence; D001713:Biphenyl Compounds / Q000378:metabolism / Q000494:pharmacology*; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D005973:Glutamine / Q000378:metabolism*; D006801:Humans; D006860:Hydrogen Bonding; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology; D054833:Isoindoles; D008969:Molecular Sequence Data; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology*; D011487:Protein Conformation; D011812:Quinuclidines / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology*; D018040:Receptors, Neurokinin-1 / Q000737:chemistry / Q000378:metabolism*
chemical_list: D001713:Biphenyl Compounds; D007211:Indoles; D054833:Isoindoles; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; D005973:Glutamine; C071693:7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one; C085215:SR 140333; C066892:CP 96345